Brokerages Set Inventiva S.A. Sponsored ADR (NASDAQ:IVA) PT at $16.56

Inventiva S.A. Sponsored ADR (NASDAQ:IVA) has been given a consensus recommendation of “Buy” by the eleven analysts that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, seven have assigned a buy recommendation and three have issued a strong buy recommendation on the company. The average 12-month price objective among analysts that have covered the stock in the last year is $16.5556.

IVA has been the subject of several analyst reports. Cantor Fitzgerald initiated coverage on shares of Inventiva in a research note on Friday. They issued an “overweight” rating for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Inventiva in a research note on Tuesday, April 21st. Finally, Wall Street Zen cut shares of Inventiva from a “hold” rating to a “sell” rating in a research note on Saturday, April 11th.

Inventiva Price Performance

Shares of IVA opened at $4.41 on Friday. Inventiva has a 52 week low of $2.85 and a 52 week high of $7.98. The stock has a 50 day moving average price of $4.33 and a two-hundred day moving average price of $5.32.

Institutional Investors Weigh In On Inventiva

Several institutional investors have recently added to or reduced their stakes in the company. Creative Planning bought a new position in Inventiva during the 2nd quarter valued at approximately $32,000. Millennium Management LLC bought a new position in shares of Inventiva in the 3rd quarter worth approximately $649,000. NewEdge Advisors LLC bought a new stake in shares of Inventiva during the third quarter valued at approximately $116,000. UBS Group AG grew its stake in Inventiva by 28,881.6% in the fourth quarter. UBS Group AG now owns 2,643,702 shares of the company’s stock worth $12,293,000 after purchasing an additional 2,634,580 shares during the period. Finally, Simplify Asset Management Inc. bought a new position in Inventiva in the fourth quarter worth $1,570,000. Hedge funds and other institutional investors own 19.06% of the company’s stock.

About Inventiva

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.